Liver X Receptor and Farnesoid X Receptor as Therapeutic Targets
- 3 December 2007
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 100 (11) , S15-S19
- https://doi.org/10.1016/j.amjcard.2007.08.008
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivoJournal of Clinical Investigation, 2007
- Impaired Development of Atherosclerosis in Hyperlipidemic Ldlr −/− and ApoE −/− Mice Transplanted With Abcg1 −/− Bone MarrowArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Decreased Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice Transplanted With Abcg1 −/− Bone MarrowArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Macrophage Reverse Cholesterol TransportCirculation, 2006
- ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulationCell Metabolism, 2005
- ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteinsProceedings of the National Academy of Sciences, 2004
- ATVB In FocusArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout miceProceedings of the National Academy of Sciences, 2001
- Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levelsJournal of Clinical Investigation, 2001
- Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR HeterodimersScience, 2000